Pinto-Merino Álvaro, Labrador Jorge, Zubiaur Pablo, Alcaraz Raquel, Herrero María José, Montesinos Pau, Abad-Santos Francisco, Saiz-Rodríguez Miriam
Department of Health Sciences, University of Burgos, 09001 Burgos, Spain.
Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain.
Pharmaceutics. 2022 Mar 3;14(3):559. doi: 10.3390/pharmaceutics14030559.
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration.
急性髓系白血病（AML）是一种异质性疾病，其特点是毒性显著且对治疗的反应差异很大。关于阿糖胞苷或蒽环类药物等经典疗法，已有大量药物遗传学研究发表，但针对新药的此类研究仍然很少。有证据表明基因多态性与治疗反应相关，尽管大多数研究在队列规模或结果标准化方面存在局限性。与基因变异性相关的不同反应包括药物疗效和毒性增加以及治疗反应降低或耐药。广泛的药物遗传学理解可能有助于设计给药策略和治疗指南。本研究的目的是对与AML药物遗传学相关的现有出版物和证据进行综述，汇编那些可能有助于优化药物给药的研究。
